CASE OF INDUCED GRAVE’S DISEASE BY NIVOLUMAB TREATMENT
DOI:
https://doi.org/10.52340/jecm.2024.03.03Keywords:
Grave’s disease, Nivolumab, hyperthyroidism, TRAbAbstract
Immune checkpoint inhibitors (ICIs) are powerful new drugs for the treatment of cancer. Immune-related adverse events (irAEs), despite their successful use in oncology, resulted in a wide range of adverse effects. Transient thyrotoxicosis and hypothyroidism cause the majority of immune-related thyroid dysfunctions, but there are also reported a few cases of ICI-induced hyperthyroidism. We present a case of Graves' disease resulted from anti-PD-1 therapy. A 63-year-old male developed tachycardia, palpitations, excessive perspiration, and vivid, horrific dreams after the sixth infusion of Nivolumab for metastatic melanoma. His thyroid function test (TFT) was abnormal, and he was treated with methimazole and propranolol. Ten weeks after starting methimazole, the TFT returned to normal, and the symptoms subsided. In a nutshell, even though Grave’s disease is a rare complication of immunotherapy, it is very important always keep it in mind to ensure quick access to prompt diagnosis and treatment to maintain a good quality of life and overall survival.
Downloads
References
Yin, Q., Wu, L., Han, L., Zheng, X., Tong, R., Li, L., Bai, L., & Bian, Y. (2023). Immune-related adverse events of immune checkpoint inhibitors: a review. Frontiers in immunology, 14, 1167975. https://doi.org/10.3389/fimmu.2023.1167975
Brancatella, A., Viola, N., Brogioni, S., et al. (2019). Graves' Disease Induced by Immune Checkpoint Inhibitors: A Case Report and Review of the Literature. European thyroid journal, 8(4):192–195. https://doi.org/10.1159/000501824
Zhan, L., Feng, H. F., Liu, H., et al. (2021, June 10). Immune Checkpoint Inhibitors-Related Thyroid Dysfunction: Epidemiology, Clinical Presentation, Possible Pathogenesis, and Management. Frontiers in Endocrinology. https://doi.org/10.3389/fendo.2021.649863
George, A. S., Fernandez, C. J., Eapen, D., & Pappachan, J. M. (2021). Organ-specific Adverse Events of Immune Checkpoint Inhibitor Therapy, with Special Reference to Endocrinopathies. European Endocrinology, 1(1), 21. https://doi.org/10.17925/ee.2021.1.1.21
Lima Ferreira J, Costa C, Marques B, Castro S, et al. Improved survival in patients with thyroid function test abnormalities secondary to immune-checkpoint inhibitors. Cancer Immunology Immunotherapy (2021) 70:299–309. doi: 10.1007/s00262-020-02664-y
Kotwal A, Gustafson MP, Bornschlegl S, Kottschade L, Delivanis DA, Dietz AB, et al. Immune checkpoint inhibitor-induced thyroiditis is associated with increased intrathyroidal T lymphocyte subpopulations. Thyroid (2020) 30:1440–50. doi: 10.1089/thy.2020.0075
Delivanis DA, Gustafson MP, Bornschlegl S, Merten MM, Kottschade L, et al. Pembrolizumab-induced thyroiditis: Comprehensive clinical review and insights into underlying involved mechanisms. J Clin Endocrinol Metab (2017) 102:2770–80. doi: 10.1210/jc.2017-00448
Corsello SM, Barnabei A, Marchetti P, de Vecchis L, Salvatori R, Torino F. Endocrine side effects induced by immune checkpoint inhibitors. J Clin Endocrinol Metab (2013) 98:1361–75. doi: 10.1210/jc.2012-4075
De Moel EC, Rozeman EA, Kapiteijn EH, Verdegaal EME, Grummels A, et al. Autoantibody development under treatment with immune-checkpoint inhibitors. Cancer Immunol Res (2019) 7:6–11. doi: 10.1158/2326-6066.CIR-18-0245
MCLACHLAN, S. M., PEGG, C. A. S., ATHERTON, M. C., et al. (1986, February). TSH RECEPTOR ANTIBODY SYNTHESIS BY THYROID LYMPHOCYTES. Clinical Endocrinology, 24(2), 223–230. https://doi.org/10.1111/j.1365-2265.1986.tb00766.x
Saito, T. (1997, October 1). Increased Expression of the Na+/I- Symporter in Cultured Human Thyroid Cells Exposed to Thyrotropin and in Graves’ Thyroid Tissue. Journal of Clinical Endocrinology & Metabolism, 82(10), 3331–3336. https://doi.org/10.1210/jc.82.10.3331
Vassart, G. (1992, August 1). The thyrotropin receptor and the regulation of thyrocyte function and growth. Endocrine Reviews, 13(3), 596–611. https://doi.org/10.1210/er.13.3.596
Morshed, S. A., Ando, T., Latif, R., & Davies, T. F. (2010, November). Neutral Antibodies to the TSH Receptor Are Present in Graves’ Disease and Regulate Selective Signaling Cascades. Endocrinology, 151(11), 5537–5549. https://doi.org/10.1210/en.2010-0424
Downloads
Published
How to Cite
Issue
Section
